Experts unpack new EGFR-mutant lung cancer first-line options, weighing survival, CNS control, and toxicity as combo regimens reshape practice.
Evolving First Line Treatment Strategies for EGFR Mutated Metastatic NSCLC
Experts weigh EGFR lung cancer combo therapies, cautioning against cross-trial comparisons and prioritizing CNS efficacy for brain metastases.
Advertisement
Advertisement
Trending on CancerNetwork
1
Cadonilimab Yields 100% 24-Month OS in Recurrent Cervical Cancer Population
2
FDA Grants Approval to Teclistamab Combo in RRMM
3
Why is the Incidence of Colorectal Cancer Rising in Young Patients?
4
Ultra-Hypofractionation Proves Feasible in Locally Advanced Breast Cancer
5